Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Zachary Crees"'
Autor:
Bahareh Mojarad, Zachary Crees, Molly Schroeder, Zhifu Xiang, Justin Vader, Jason Sina, John Frater, Eric Duncavage, David Spencer, Julie Neidich, Kory Lavine, Ina Amarillo
Publikováno v:
Cancer Genetics. :33-34
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9da85f2f40e6bdf33cf2b4e4f5d7f20
https://doi.org/10.1016/j.cancergen.2022.10.108
https://doi.org/10.1016/j.cancergen.2022.10.108
Autor:
Michael Slade, Mark Fiala, Sarah Kelley, Zachary Crees, Mark Schroeder, Keith Stockerl-Goldstein, Ravi Vij
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S20-S21
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa09b98dd2a07679d2377c07d9fd889d
https://doi.org/10.1016/s2152-2650(22)00307-x
https://doi.org/10.1016/s2152-2650(22)00307-x
Autor:
Odile David, Zachary Crees, Austin D. Anderson, Kavin Arasi, Ariana Munger, Lin Leo S, Caleb Shearrow, Christian Garcia, Thomas J. Smith, Neelu Puri, Shylendra Sreenivassappa, Aayush Bhoraskar, Sunil Palani, Jennifer Girard, Adam Eckburg, Connie Vitali, Joseph Berei
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Background:EGFR/c-Met activation/amplification and co-expression, mTOR upregulation/activation, and Akt/Wnt signaling upregulation have been individually associated with more aggressive disease and characterized as potential prognostic markers for lu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c168ed28adc5c8b745194be9d014cec6
https://doaj.org/article/8c227a1782da4256ae9803b9ba799ade
https://doaj.org/article/8c227a1782da4256ae9803b9ba799ade
Autor:
Inbal Goldstein, Keith Stockerl-Goldstein, Ella Sorani, Tahir Latif, Gemma Moreno Jiménez, Maria Liz Paciello Coronel, John W. Hiemenz, Abi Vainstein, Árpád Illés, Zachary Crees, Irit Gliko-Kabir, Massimo Martino, Muzaffar H. Qazilbash, Sarah Larson, Udo Holtick, Patrick J. Stiff, Gabor Mikala, Douglas W. Sborov, Giuseppe Milone, Irene García-Cadenas, John F. DiPersio, Nancy M. Hardy, Shaul Kadosh, Ivana N. Micallef, Denise Pereira
Publikováno v:
Blood. 138:475-475
Background: Autologous stem cell transplantation (ASCT) in multiple myeloma (MM) has been shown to improve survival compared to conventional chemotherapy alone. However, the ability to perform ASCT relies, in part, on collecting a sufficient number (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a686c39b1f29032b61a0b706fc5c8c7a
https://doi.org/10.1182/blood-2021-144296
https://doi.org/10.1182/blood-2021-144296
Autor:
Keith Stockerl-Goldstein, Liron Shemesh-Darvish, Denise Pereira, John F. DiPersio, Sarah Larson, Nancy M. Hardy, Udo Holtick, Michael Retting, Shaul Kadosh, Giuseppe Milone, Patrick J. Stiff, Irene García-Cadenas, Ella Sorani, Ivana N. Micallef, Gabor Mikala, Douglas W. Sborov, Maria Liz Paciello Coronel, Abi Vainstein, Tahir Latif, Muzaffar H. Qazilbash, Zachary Crees, Massimo Martino, Gemma Moreno Jiménez, John W. Hiemenz, Árpád Illés
Publikováno v:
Blood. 138:2849-2849
Background: CD34+ hematopoietic stem and progenitor cell (HSPC) dose during hematopoietic cell transplantation (HCT) remains one of the most reliable clinical parameters to predict quality of engraftment. A minimum HSPC dose of 2-2.5x10 6 CD34+ cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e430c6b3c970e2560deaf6b241af447e
https://doi.org/10.1182/blood-2021-146783
https://doi.org/10.1182/blood-2021-146783
Autor:
Keith Stockerl-Goldstein, Michael Retting, Liron Shemesh-Darvish, Reyka G Jayasinghe, John F. DiPersio, Abi Vainstein, Shaul Kadosh, Debby Ickowicz, Zachary Crees, Ella Sorani
Publikováno v:
Blood. 138:3816-3816
Background: CD34 expression remains the most common immunophenotypic cell surface marker defining human hematopoietic stem and progenitor cells (HSPCs). Recently, use of multicolor fluorescence-activated cell sorting (mFACS) and single-cell RNA seque
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89ca930e85867d3611ad01f9f9f96f6d
https://doi.org/10.1182/blood-2021-144297
https://doi.org/10.1182/blood-2021-144297
Autor:
Zachary Crees, Armin Ghobadi
Publikováno v:
Cancers
Cancers, Vol 13, Iss 5181, p 5181 (2021)
Cancers, Vol 13, Iss 5181, p 5181 (2021)
Simple Summary B-cell lymphomas are the most commonly occurring blood cancer and the second leading cause of cancer-related death among blood cancers. Chemotherapy and stem cell transplantation have long served as the standard therapies for relapsed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93aa2bbab408098ea64746af61c4169c
https://doi.org/10.3390/cancers13205181
https://doi.org/10.3390/cancers13205181
Publikováno v:
Journal of Pancreatic Cancer
Journal of Pancreatic Cancer, Vol 3, Iss 1, Pp 49-52 (2017)
Journal of Pancreatic Cancer, Vol 3, Iss 1, Pp 49-52 (2017)
Background: Gemcitabine, alone or in combination with other agents, has become an important part of the standard of care for treatment of both resectable and unresectable/advanced pancreatic adenocarcinoma. Gemcitabine is generally considered to have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4ddc3211657e767277a9f5e82934b58
https://doi.org/10.1089/pancan.2017.0012
https://doi.org/10.1089/pancan.2017.0012
Publikováno v:
Future Oncol
Effective hematopoietic cell transplantation relies upon collecting adequate numbers of CD34+ hematopoietic stem cells, typically from peripheral blood. A minimum of ≥2 × 106 CD34+ cells/kg are necessary, while transplants of ≥5–6 × 106 CD34+
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39cbac9e8ca7bec7123f7a96aee809ab
https://pubmed.ncbi.nlm.nih.gov/31495201
https://pubmed.ncbi.nlm.nih.gov/31495201
Autor:
Zachary Crees, Nathan W. Sweeney, Eduardo Franco Hernandez, Scott R. Goldsmith, Nolan Cole, Jenny Ahlstrom
Publikováno v:
Journal of Clinical Oncology. 39:e20024-e20024
e20024 Background: Chimeric antigen receptor (CAR) T-cell therapies are in clinical development for multiple myeloma (MM). Patient-reported outcomes (PRO) can provide valuable insights into how patients perceive the relative risks and benefits of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd136c8d05dc2df11262ecbd4455a513
https://doi.org/10.1200/jco.2021.39.15_suppl.e20024
https://doi.org/10.1200/jco.2021.39.15_suppl.e20024